Reich K, Augustin M, Thaçi D, et al. - Since interleukin-17 antagonists have received the first-line label for moderate-to-severe plaque psoriasis, researchers carried out the first head-to-head trial between the two most commonly used first-line therapies in Germany, fumaric acid esters (FAEs) and methotrexate, and the interleukin-17A antagonist, ixekizumab. This trial was carried out at 28 study sites in Germany between January and December 2016. Participants in the study were randomized 1 : 1 : 1 to FAEs, methotrexate or ixekizumab via an interactive web response system. A total of 162 individuals have been randomized. Compared with methotrexate and FAEs, ixekizumab was superior in inducing PASI 75/90/100, sPGA (0,1) and DLQI (0,1) responses at week 24. Safety profiles were consistent with previous studies for all treatments. This investigation proved the advantage of the IL-17A antagonist ixekizumab over the conventional therapies FAEs and methotrexate.